MedTrace Logo

Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors

NCT07644650 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-06-12

No results posted yet for this study

Summary

A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.

Conditions

  • Neoplams

Interventions

BIOLOGICAL

MST-168

MST-168 is a proprietary antibody-drug conjugate (ADC) developed by Mabsoft Therapeutics.

Sponsors & Collaborators

  • Mabsoft Therapeutics (Australia) Pty. Ltd.

    collaborator UNKNOWN

  • Mabsoft Therapeutics (Guangdong Hengqin) Co., Ltd.

    collaborator UNKNOWN

  • Mabsoft Therapeutics (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2028-06-30
Completion
2030-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07644650 on ClinicalTrials.gov